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1. Introduction 
 
1.1 General introduction 
 
Coronary heart disease is the leading cause of death world wide. 3.4 million 
women and 3.8 million men die each year from Coronary Heart Disease 
(CHD). Major risk factors are high blood pressure, high blood cholesterol, 
smoking, physical inactivity, unhealthy diet, diabetes, advancing age, male sex 
and genetic disposition (Niccoli, Iacoviello et al. 2001; Yusuf, Reddy et al. 
2001; Yusuf, Reddy et al. 2001). A decline in death rates from CHD over the 
past decades has been reported for North America and many western 
European countries. Improved prevention, diagnosis and treatment are 
thought to be responsible for this decrease (Rosamond, Folsom et al. 2001; 
Fox, Evans et al. 2004; Unal, Critchley et al. 2004; Fox, Steg et al. 2007). 
The present study examines the effect of new treatment strategies for Acute 
Myocardial Infarction (AMI) on long-term survival after a first AMI from the 
KORA Coronary Event Registry (WHO-MONICA Project/KORA-Initiative) 
(Lowel, Lewis et al. 1991) in the region of Augsburg, Southern Germany. 
 
1.2 Background 
 
1.2.1 Definition and symptoms of Acute Myocardial Infarction  
 
AMI usually develops on the basis of atherosclerosis in the coronary arteries. 
Inflammation leads to the rupture of atherosclerotic plaques, a process that 
causes stenosis of the coronary arteries which supply the heart muscle with 
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the oxygen that it needs to work properly. Depending on the degree of 
stenosis, the reduced blood flow may cause conditions from angina pectoris 
without damage of the myocardium to acute myocardial infarction with 
myocardial necrosis or even sudden cardiac death. AMI is defined as necrosis 
of myocardial tissue due to reduced or missing blood flow in the coronary 
arteries which leads to oxygen deficiency in the heart muscle. 
Patients with AMI present with symptoms like long lasting thoracic pain 
(angina pectoris) which is not relieved through rest or the application of nitro-
glycerine, ventricular arrhythmia, feelings of fear and feebleness and 
vegetative symptoms like shortness of breath, nausea, sweating, vomiting and 
others. Blood pressure is often low, but high or normal pressure is possible as 
well. About one third of the patients show symptoms of a left ventricular 
insufficiency. 
 
1.2.2 Diagnostic criteria 
 
Until recently medical doctors used differing definitions of myocardial infarction 
depending on whether their emphasis was on clinical, electrocardiographic, 
biochemical or pathologic characteristics of AMI. Neither the ECG nor the 
clinical history has the sensitivity or specificity to diagnose all myocardial 
infarctions correctly (White 2008). The WHO MONICA (MONitoring trends and 
determinants of CArdiovascular disease) definition of acute myocardial 
infarction was based on typical symptoms (e.g. chest pain), 
electrocardiographic changes corresponding to myocardial necrosis and 
elevation of serum enzymes, especially CKMB (creatine kinase myocardial 
band). The combination of two out of these three characteristics led to the 
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diagnosis “AMI” until new diagnostic criteria were established. In the year 2000 
the European Society of Cardiology (ESC) and the American College of 
Cardiology (ACC) published a consensus document for the redefinition of 
myocardial infarction (The Joint European Society of Cardiology/ American 
College of Cardiology Committee 2000). 
With the introduction of cardiac troponins T and I as indicators of myocardial 
necrosis the sensitivity and specificity of serologic biomarkers increased, 
because troponins are specific for myocardial tissue and even microscopic 
necrotic lesions in the myocardium lead to the detection of increased troponin 
levels in the serum. More precise imaging techniques also facilitate the 
discovery of microscopic areas of myocardial necrosis. As a consequence the 
consensus conference proposed that “any amount of myocardial necrosis 
caused by ischemia should be labelled as an infarct” (The Joint European 
Society of Cardiology/ American College of Cardiology Committee 2000). The 
new definition of myocardial infarction was published by the conference in the 
year 2000 and is cited here: 
“Either one of the following criteria satisfies the diagnosis for an acute, 
evolving or recent MI: 
1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CKMB) of 
biochemical markers of myocardial necrosis with at least one of the following: 
a) ischemic symptoms; 
b) development of pathologic Q waves on the ECG; 
c) ECG changes indicative of ischemia (ST segment elevation or depression); 
or 
d) coronary artery intervention (e.g., coronary angioplasty). 
2. Pathologic findings of an acute MI.” 
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The modification of the definition of AMI was expected to lead to an increase 
in the identification of cases of AMI due to the higher sensitivity and to the 
reduction of missed cases due to the increased specificity.  
The introduction of the new definition of AMI in the clinical routine poses a 
problem for epidemiologic research and Coronary Event Registries in principle 
though. A change in definition causes incomparability of data from before the 
change with data afterwards. The Coronary Event Registry (CER) Augsburg 
continued to use the WHO-MONICA criteria of AMI definition to secure the 
comparability throughout the years. In the year 2001 the CER started to 
document the troponin values, but troponin was not included in the algorithm 
to derive the AMI cases. The influence of the new definition on the CER 
cannot completely be avoided, because clinicians started to use the new 
definition of AMI, which eventually led to change in the composition of the 
patient population presented for selection to the registry. The influence of 
these changes is one topic of the present work. 
 
1.2.3 Treatment of AMI 
 
The Task Force on the Management of Acute Myocardial Infarction of the 
European Society of Cardiology published their report in the year 2002 with 
new recommendations for the treatment of AMI (The Task Force on the 
Management of Acute Myocardial Infarction of the European Society of 
Cardiology, Van de Werf et al. 2003). Three phases of treatment with three 
different aims have to be considered. In the first phase of the acute event the 
relief of pain, breathlessness and anxiety are predominantly warranted. 
Intravenous opioids, the application of oxygen and eventually β-blockers or 
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nitrates and tranquillizers are given to reach this primary goal. The second 
phase consists in the restoration of coronary flow and myocardial tissue 
reperfusion either still in the pre-hospital or in the early in-hospital setting 
under the condition that no contraindications exist. Mechanical or 
pharmacological reperfusion can be distinguished. Percutaneous coronary 
intervention (PCI) with or without stent implantation is the mechanical 
reperfusion treatment and must be divided into primary PCI, PCI combined 
with pharmacological reperfusion and “rescue PCI” when pharmacological 
reperfusion failed. Coronary artery bypass surgery is rarely needed in the 
acute phase of myocardial infarction, but may be performed if PCI is 
contraindicated or failed to achieve reperfusion or caused another occlusion 
during catheterization. Fibrinolytic reperfusion treatment is performed with 
activators of fibrinolysis like streptokinase and tissue plasminogen activator or 
anistreplase. A short time to treatment is required for all types of reperfusion to 
obtain the lowest possible mortality and re-infarction rate.  
The third phase of treatment comprises the secondary prevention to avoid re-
infarction and death. Apart from changes in life style like cessation of smoking, 
moderate physical activity, healthy diet and optimal control of blood sugar in 
diabetic patients, pharmacological treatment is necessary. Clinical trials have 
shown that anticoagulants and antiplatelet medication, like low-dose aspirin, 
and β-blockers are effective in preventing re-infarction and death. Antipatelets 
and anticoagulants prevent the formation of new blood clots which could lead 
to renewed occlusion of the coronary arteries. β-blockers help to control blood 
pressure in hypertensive patients. In addition to these established medications 
Angiotensin-converting enzyme inhibitors (ACE-inhibitors) and lipid lowering 
agents, especially statins are now recommended as secondary prevention 
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treatment. ACE-inhibitors are known to reduce remodelling processes of the 
heart, which could lead to an expansion of the infarction scar and to the 
hypertrophy and dilatation of the left ventricle (Herold 2007). Lipid-lowering 
agents should be prescribed if the total cholesterol level is greater than 190 
mg/dl and/or the Low-Density-Lipoprotein (LDL) cholesterol level is greater 
than 115 mg/dl (The Task Force on the Management of Acute Myocardial 
Infarction of the European Society of Cardiology, Van de Werf et al. 2003).  
The treatment of AMI has changed considerably during the last decades. 
Before the publication of the new treatment recommendations the application 
of PCI was done in cardiologic centres and pharmacological fribrinolysis 
played a more significant role in the treatment of AMI patients. With the 
establishment of the effectiveness of PCI treatment it became obvious that the 
more widespread use of the method was warranted and the acquirement of 
knowledge, practice and facilities in more hospitals was successfully 
promoted. 
 
1.2 Aims of the present study 
 
The change of diagnostic criteria of AMI led to an increase of AMI diagnoses 
(White 2008) on the clinical level. The registry continued to use the WHO 
criteria for myocardial infarction and classified the additionally diagnosed AMIs 
either as definite or possible AMI. It is hypothesized that the composition of the 
two categories has changed in respect of the number of cases and the type of 
infarction. Therefore the present study describes how the change of diagnostic 
criteria in the clinical setting affects the numbers and types of registered 
events over the course of the years 1995 through 2003 at the CER Augsburg.  
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The application of invasive and pharmacological treatments over the years is 
documented in the CER. The changes in treatments of patients with AMI and 
the implementation of the new treatment recommendations will be assessed.  
The main question of interest though is to examine the long-term mortality and 
re-infarction rate over time in the light of the changed diagnostic criteria and 
therapeutic guidelines. Therefore the mortality and re-infarction rates will be 
compared between patients who were registered between 1995 and 1999 and 
patients who were registered between 2000 and 2003 with a first myocardial 
infarction. 
 
2. Material and methods 
 
2.1 Study population and study design  
 
The Coronary Event Registry (CER) Augsburg was founded in 1984 in the 
context of the WHO MONICA studies to assess the incidence of myocardial 
infarctions in southern Germany. Since then the Coronary Event Registry has 
aimed to register every case of non-fatal myocardial infarction and fatal 
coronary death (WHO MONICA Project Principal Investigators 1988; Lowel, 
Lewis et al. 1991). The MONICA project ended in 1995, but the CER was 
continued as part of the KORA (Cooperative Health Research in the Region of 
Augsburg) initiative. The CER is located in the main hospital of Augsburg 
(Augsburg Central Hospital) and registers persons with myocardial infarction 
who are between 25 and 74 years old and are residents of the city of 
Augsburg or the two adjacent counties of “Aichach/Friedberg” and “Augsburg”.  
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In the year 2000 approximately 200 000 men and 202 000 women between 25 
and 74 years were living in the study area. 
All cases of AMI that occurred over the study period were followed up with 
respect to survival until 31st of December 2005. Recurring AMI events were 
linked to the individual. The present study is conducted as a cohort study with 
AMI as index event and mortality as well as re-infarction as outcome.  
 
2.2 Case finding and data collection 
 
To ascertain recording of subjects surviving the index event for at least 24 
hours, trained nurses from the CER routinely checked the admission books 
from emergency room, intensive care unit and cardiac wards in the Hospital of 
Augsburg on a daily basis for coronary events. Physicians on cardiac wards in 
the eight other hospitals in the study area were called by phone at least once 
a week and asked for hospitalized AMI cases under their care. A list of 
suspected coronary event cases was created by the nurses and replaced by a 
list of confirmed cases when the treating physicians were contacted and 
confirmed the diagnosis. The final decision on the AMI diagnosis for the CER 
was not based on the clinical diagnosis but an algorithm that combined the 
information gathered from different sources (see 2.3).  Patients with a clinically 
confirmed diagnosis of AMI were asked to participate in the Coronary Event 
Registry. In case of their informed consent a standardized interview was 
conducted by a trained nurse three or four days after the acute event. 
Questions were asked about their socio-demographic characteristics, the 
acute event, their family history, their medical history, medication and coronary 
risk factors. Information on diagnostic measures, treatment and medication 
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during hospitalization was derived through a concluding hospital chart review 
by means of a standardized protocol. All data were fed into the computer 
including the ICD codes of discharge diagnoses. 
 
2.3 Case definition of the index event 
 
All non-fatal definite incident cases of myocardial infarction, which were 
registered between 1995 and 2003 in the CER were included (index event) in 
the study presented here. The definition of non-fatal was based on a 28 day 
survival criterion. Incident cases are subjects that have not had a previous 
AMI. The three MONICA diagnostic criteria are acute chest pain, which lasts 
for more than twenty minutes and is resistant to treatment with nitrates, 
elevated heart muscle specific enzymes (either creatinine phosphokinase or 
aspartate aminotransferase or lactate dehydrogenase) to more than twice the 
upper limit of normal enzyme levels and typical ECG changes. AMIs were 
divided into four different categories. A definite case of AMI existed, if ECG 
changes showed transmural infarction or if ECG changes were typical for 
posterior or anterior infarction, typical symptoms (any pain or pressure, 
tightness or burning sensation in the chest with a duration of more than 20 
minutes) were reported and enzymes showed double elevation, or if ECG was 
missing, but symptoms were typical and enzymes were doubled. A case of 
AMI was considered as possible AMI if typical symptoms were reported, ECG 
changes showed anterior or posterior infarction or ECG was missing and the 
enzymes were unspecific, normal, doubtful, not complete or had not been 
determined. The other two categories are ischemic AMI and insufficient data, 
which both were excluded from the analysis. 
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2.4 Definitions and formation of variables  
 
Age was calculated as age in years at the time of the event and grouped in ten 
year classes (25 to 34, 35 to 44, 45 to 54, 55 to 64 and 65 to 74 years). 
Registration ended with the 75th birthday of a person. 
The area of residence was divided into “urban” for persons who live in 
Augsburg city and “rural” for persons who live in either county 
Aichach/Friedberg or Augsburg.  
In the interview patients reported about the type of school they visited and the 
highest degree they obtained. Education time was calculated with this 
information and categorized into 12 or more years or less than 12 years. 
Marital status and cohabitation status were assessed and dichotomized into 
married or not married and living alone or not living alone.  
Knowledge on preexisting illnesses was based on the information given by the 
patient during the interview or medical records. Angina, 
hypercholesterinaemia, hypertension, stroke and diabetes were therefore 
categorized into unknown, yes (the illness was diagnosed before 
hospitalization) or no (neither the physician nor the patient was aware of a 
preexisting condition). 
The body mass index was calculated from information in the medical records 
and was dichotomized into ≥30 kg/m² and <30 kg/m². 
Smoking status was also available from the interview as never smoker, ex-
smoker and current smoker. 
Medication at discharge as well as invasive treatment was derived from the 
medical records and was classified as present or absent for each patient. The 
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included groups of medications in the present study were antiplatelets, β-
blockers, statins and ACE-inhibitors. PCI without stent, PCI with stent 
implantation, Coronary Artery Bypass Grafting (CABG) and pharmacological 
lysis were considered as invasive treatments. 
 
2.5 Exposure of interest 
 
Treatment of AMI changed considerably with the implementation of new 
therapeutic guidelines in the year 2000. At the same time diagnostic criteria 
were altered. To examine whether these changes influenced the survival after 
AMI the study sample was divided into two groups depending on the year in 
which a person had his/her first AMI either from 1st January 1995 to 31st 
December 1999 or from 1st January 2000 to 31st December 2003. To assess 
whether this division represented changes in mortality and re-infarction rates 
well an additional analysis was done using PCI with stent or no stent as 
exposure of interest, because the treatment with stents was the major change 
of treatment following the new guidelines. 
 
2.6 Follow-up of mortality  
 
The registry received the death certificates with suspected underlying cardiac 
causes on a regular basis from the three local health departments. The 
registry team checked routinely whether any of the deceased are registered in 
the CER and if applicable updated the record by adding the date and cause 
(ICD codes) of death. Active mortality follow-ups were performed to 
supplement this source of information. An independent institution was 
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authorized to check the existing addresses of the patients with the local 
registration offices to update the information if patients had moved or died. 
The last mortality follow-up was started in December 2005 and lasted about 4 
months. The data for the present study were censored at the 31st December 
2005.  
 
2.7 Follow up of re-infarction  
 
Re-infarctions of persons who were between 25 and 74 years old and were 
admitted to one of the hospitals in the study region are included in the CER as 
a new case. Name and birth date were checked at the beginning of the 
admission procedure for already existing cases of the person. If a person has 
records on a first AMI in the registry the following cases of AMI will be marked 
as re-infarction (1, 2,…). The second endpoint besides mortality in the present 
study was the first re-infarction after the first acute event. All patients were 
censored at their 75th birthday, because the registry does not admit persons or 
cases over 75 years of age. 
 
2.8 Statistical analysis 
 
Sex-specific frequencies and age adjusted prevalences were calculated for all 
covariates. Logistic regression was used to compare the two time periods of 
first AMI (from 1st January 1995 to 31st December 1999=Study Period 1 and 1st 
January 2000 to 31st December 2003=Study Period 2) and the two treatment 
groups (PCI with stent and without stent) with regard to differing age adjusted 
prevalence of covariates in the respective sub-groups. The duration of follow-
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up was derived from the difference between the date of first AMI and the date 
of death or the last follow-up information or the 31st December 2005. Crude 
sex-specific mortality and re-infarction rates were calculated per 1000 person 
years (pyrs) for one year, three years and the whole time of follow-up.  
Kaplan-Meier survival curves were created with the outcome death and re-
infarction. The subsequent analyses were stratified by sex. The association 
between time periods of first AMI (Study Period 1 and 2) and mortality or re-
infarction rate was examined using Cox proportional hazards models. The 
proportional hazards assumption for all factors used in the Cox models was 
checked plotting log (-log (event)) versus log of event times. None of the 
covariates seemed to violate the PH assumption.  At first the crude association 
between time periods and mortality/re-infarction rate was calculated. In a 
second step the model was adjusted for age as a continuous variable. 
Subsequently the model adjusted for socio-demographic variables (area of 
residence, education time, marital status, cohabitation status, working), 
preexisting diseases (angina, stroke, hypertension, hyperlipidaemia, diabetes), 
BMI, smoking (never, ex, actual), discharge medication (β-blocker, ACE-
inhibitors, antiplatelets, statins) and invasive medical treatment during 
hospitalization (lysis, PCI with stent, PCI without stent, CABG). The following 
model contained only variables which showed significant influence in one of 
the former models at the 10% level. Consecutively all covariates were 
excluded following the same method until every covariate included in the 
model had a significant effect on mortality/re-infarction rate at the 10% level. 
Significance tests were two tailed and p-values less than 0.05 were stated as 
statistically significant. All analyses were performed using the Statistical 
Analysis System (Version 9.1, SAS Institute Inc., Cary, NC). 
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3. Results 
 
3.1 Derivation of the study sample 
 
Due to the changes of diagnostic criteria for myocardial infarction on the 
clinical level and the suspected influence on the registration of cases, it was 
important to find relatively homogeneous groups of AMI cases which could be 
compared for their mortality and re-infarction rates.  Figure 1 shows that the 
percentage of persons who survived the first 28 days rose from between 50 
and 60% in the year 1995 to 70% in the years 2001 to 2003 when including all 
incident MI cases 1995 to 2003 of all four diagnostic categories.  
Figure 1: 28-day survival of patients with first AMI (index event) per 
year
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Only cases with possible or definite AMI by sex are shown in figure 2 and 3. 
Figure 2: 28-day survivors of definite or possible first AMI per year
0
50
100
150
200
250
300
1995
1996
1997
1998
1999
2000
2001
2002
2003
N
um
be
r o
f p
at
ie
nt
s
definite MI men
possible MI men
definite MI women
possible MI women
 
Figure 3: Distribution of definite and possible AMI in 28-day 
survivors  
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Figure 2 confirms the increase of the absolute number of cases during the 
examined study period. More men with definite AMI survived the first 28 days 
after infarction, but also the number of women and men with possible AMI rose 
from 8 and 17 in the year 1995 to 46 and 82 respectively in the year 2003. 
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Accordingly the frequency distribution of AMI cases of the years 2000 and 
2003 differs from the distribution of cases between the years 1995 and 1999 in 
that the percentage of possible AMIs has risen to around thirty percent for both 
sexes (Figure 3). The increase of possible AMI cases was probably due to the 
change of diagnostic criteria and led to the conclusion that a comparison of the 
two study periods would become difficult if the inhomogeneous group of 
possible AMIs was kept in the analysis.  Possible AMIs were therefore 
excluded from analyses. The remaining study sample comprised 2911 
persons with definite AMI, 700 of them were women and 2211 were men 
(figure 4). 
Figure 4: Flowchart on the derivation of the study sample 
 
 
3.2 Description of the study sample 
In crude analyses the absolute number of AMI increased with age for both 
sexes. Up to the age of 64 years the number of cases in men was 3 times the 
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number of cases in women. This discrepancy is somewhat reduced in the 65 
to 74 year olds (figure 5). 
Figure 5: Number of  incident definite AMI’s by age and 
sex  between 1995 and 2003 in Augsburg Germany
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In this oldest age-group 50% of the AMIs among women occurred, whereas 
AMIs in men were more evenly distributed between 45 and 74 years of age 
(figure 6).  
Figure 6: Age distribution for women and 
men
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The frequency distribution of socio-demographic characteristics, pre-existing 
diseases and cardiovascular risk factors in men and women by study period 
are shown in table 1 and 2. 
Table 1: Socio-demographic characteristics of the study sample 
Sociodemographic 
characteristics 
Women Men 
all Study period Study period 
≤31dec99 >31dec99 ≤31dec99 >31dec99 
N % N % N % N % N 
Employment status 
unknown 57 15.3 17 5.2 100 8.7 40 3.8 214 
no 259 69.4 248 75.8 543 47.3 545 51.2 1595 
yes 57 15.3 62 19.0 504 43.9 479 45.0 1102 
Years of education
unknown 75 20.1 70 21.4 197 17.2 204 19.2 546 
≥12 years 17 4.6 10 3.1 143 12.5 119 11.2 289 
< 12 years 281 75.3 247 75.5 807 70.4 741 69.6 2076 
Nationality  
unknown . . . . 2 0.2 1 0.1 3 
other 18 4.8 15 4.6 101 8.8 107 10.1 241 
german 355 95.2 312 95.4 1044 91.0 956 89.8 2667 
Area of residence 
rural 170 45.6 164 50.2 598 52.1 578 54.3 1510 
urban 203 54.4 163 49.8 549 47.9 486 45.7 1401 
Marital status 
unknown 17 4.6 7 2.1 20 1.7 12 1.1 56 
not married 133 35.7 130 39.8 192 16.7 208 19.5 663 
married 223 59.8 190 58.1 935 81.5 844 79.3 2192 
Living alone 
unknown 18 4.8 29 8.9 34 3.0 54 5.1 135 
no 264 70.8 213 65.1 1012 88.2 898 84.4 2387 
yes 91 24.4 85 26.0 101 8.8 112 10.5 389 
 
All 373 100.0 327 100.0 1147 100.0 1064 100.0 2911 
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Table 2: Frequency distribution of pre-existing diseases and risk factors 
 
Diseases and 
risk factors 
Women Men 
all Study period Study period 
≤31dec99 >31dec99 ≤31dec99 >31dec99 
N % N % N % N % N 
Angina  
unknown 1 0.3 . . 5 0.4 2 0.2 8 
no 323 86.6 278 85.0 1002 87.4 937 88.1 2540 
yes 49 13.1 49 15.0 140 12.2 125 11.7 363 
Stroke  
unknown 7 1.9 39 11.9 17 1.5 134 12.6 197 
no 346 92.8 259 79.2 1099 95.8 877 82.4 2581 
yes 20 5.4 29 8.9 31 2.7 53 5.0 133 
Diabetes  
unknown 1 0.3 . . 3 0.3 . . 4 
no 268 71.8 230 70.3 901 78.6 771 72.5 2170 
yes 104 27.9 97 29.7 243 21.2 293 27.5 737 
Hypertension  
unknown 1 0.3 . . 2 0.2 3 0.3 6 
no 126 33.8 69 21.1 508 44.3 345 32.4 1048 
yes 246 66.0 258 78.9 637 55.5 716 67.3 1857 
Hyperlipidemia  
unknown 6 1.6 3 0.9 19 1.7 11 1.0 39 
no 129 34.6 74 22.6 367 32.0 234 22.0 804 
yes 238 63.8 250 76.5 761 66.3 819 77.0 2068 
BMI (kg/m2)  
unknown 19 5.1 11 3.4 38 3.3 33 3.1 101 
BMI<25 131 35.1 116 35.5 359 31.3 304 28.6 910 
25≥BMI<30 152 40.8 119 36.4 561 48.9 521 49.0 1353 
BMI≥ 30 71 19.0 81 24.8 189 16.5 206 19.4 547 
Smoking   
unknown 18 4.8 31 9.5 21 1.8 60 5.6 130 
current 
smoker 129 34.6 102 31.2 505 44.0 410 38.5 1146 
ex-smoker 42 11.3 46 14.1 332 28.9 340 32.0 760 
never smoker 184 49.3 148 45.3 289 25.2 254 23.9 875 
  
All 373 100.0 327 100.0 1147 100.0 1064 100.0 2911 
 
 
Several of the examined parameters showed differences between the 
compared study periods in women and men. During the years 2000 to the 
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2003 more subjects were identified to have had a stroke before hospitalization 
or to suffer from hypertension, hyperlipidemia or diabetes. The number of 
actual smokers decreased slightly in the same period of time. To assess 
whether these differences were significant, age adjusted prevalences in both 
groups were calculated and compared by using logistic regression. For easier 
comparison BMI was grouped into two categories for the following 
calculations. Women and men showed the same tendency of changes in the 
frequency distribution and age adjusted prevalence is presented for both 
sexes together. 
 
Table 3: Age adjusted prevalence of socio-demographic characteristics, pre-existing 
diseases and cardiovascular risk factors  
 Study period  
Variable ≤31dec99 >31dec99   
 Prevalence 95%-C.I. Prevalence 95%-C.I. *p-value 
Men 76.3 74.1 78.4 77.5 75.2 79.7 0.4451 
Urban 49.5 47.0 52.0 46.7 44.0 49.3 0.1278 
Education time≥ 12 years 12.6 10.8 14.5 11.4 9.6 13.4 0.3632 
Married 78.1 75.9 80.1 75.4 73.0 77.6 0.084 
Living alone 13 11.4 14.8 14.9 13.1 17.0 0.1419 
Working 36.3 32.9 39.8 38 34.5 41.7 0.491 
  
Angina 11.9 10.3 13.6 11.8 10.2 13.6 0.9705 
Hypertension 58.7 56.1 61.2 71.1 68.6 73.5 <.0001 
Hyperlipidemia 66.9 64.5 69.3 77.8 75.6 80.0 <.0001 
Stroke 3 2.2 3.9 5.9 4.6 7.4 <.0001 
Diabetes 22.4 20.4 24.6 27.5 25.2 29.9 0.0017 
   
BMI ≥ 30 kg/m2 17.7 15.8 19.7 21.3 19.2 23.5 0.017 
Never smoker 29.9 27.5 32.4 28.9 26.4 31.6 0.5775 
Ex-smoker 24.7 22.5 27.0 29.2 26.8 31.8 0.0075 
Current smoker 42.3 39.5 45.0 37.9 35.1 40.8 0.0311 
*p-value derived through logistic regression by comparing the two study periods 
regarding the age adjusted prevalences of each variable 
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The differences seen in the crude frequency distributions were confirmed by 
comparison of the study periods through logistic regression as shown in table 
3. Significantly more persons reported stroke, hypertension, hyperlipidemia or 
diabetes in Study period 2 compared to Study period 1. The prevalence of 
persons with a BMI above 30 kg/m2 had increased significantly. Fewer patients 
were actual smokers, and more had given up smoking in the past. 
 
3.3 Description of treatment 
The changes of the treatment guidelines for myocardial infarction are reflected 
by the actual clinical practice. Figures 7 and 8 show the development of 
discharge medication and invasive treatment during hospitalization in the 
course of years. 
Figure 7: Discharge medication by year of event
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Figure 8: Invasive treatment by year of event
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ACE-inhibitors as well as statins show a steady increase over the years. In the 
years 2002 and 2003 over 80% of patients in the study sample received a 
prescription for both medications at discharge from the hospital compared to 
less than 40% in 1995. The implementation of the PCI with stent started in the 
year 1999 and continued until 2002 and 2003 where it seems to have reached 
a peak with over 60% of patients being provided with such a therapy. With the 
rise of the stent therapies like lysis and PCIs without stent have been used 
less and less frequently. These changes are reflected in table 4 that compares 
treatment prevalences of Study period 1 and Study period 2. 
Table 4: Age adjusted prevalence of treatment  
  Study period   
Treatment ≤31dec99 >31dec99   
 Prevalence (%) 95%-C.I. Prevalence (%) 95%-C.I. *p-value
Lysis 46.8 44 49 26.8 25 29 <.0001 
PCI with stent 5.5 4.5 6.8 54 51.4 56.6 <.0001 
PCI w/o stent 22.2 20.1 24.4 6 4.8 7.3 <.0001 
Bypass 10 8.6 11.6 15.7 13.9 17.7 <.0001 
                
Antiplatelets 89.5 87.9 91.0 95.6 94.4 96.6 <.0001 
β-Blockers 85.7 83.9 87.4 95 93.7 96.0 <.0001 
Statins 40.6 38.1 43.1 80.6 78.4 82.6 <.0001 
ACE-inhibitors 44.1 41.6 46.6 76.5 74.2 78.7 <.0001 
*p-value derived through logistic regression by comparing the two study periods 
regarding the age adjusted prevalences of each treatment 
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3.4 Mortality 
Follow up time overall was on average 5.6 years with a maximum of 10 years 
for those with their index event in 1995 and a minimum of 2 years for those 
entering the cohort in 2003. Given by this design the average follow up time 
was 7.4 years for those subjects who were entered in Study Period 1 and 3.8 
years for subjects of Study Period 2. Crude mortality rates per 1000 person 
years were calculated for the total time, three years and one year of follow-up, 
assuming that mortality rates are more comparable within these time windows 
(Table 5). Mortality was higher for the group of the first study period regardless 
of the length of follow-up time and sex. Considering the maximum follow-up 
time, total mortality was much higher in Study period 1 compared to Study 
period 2 which is explained by the length of observation period. This is not true 
for women whose one and three year follow-up mortalities are much higher in 
the first cohort than in the second one whereas this difference is smaller when 
calculated for the total follow-up time. For all follow-up times the calculated 
mortality was higher in women than in men. Until the 31st December 2005 331 
men and 133 women have died. 62 men died within the first year after their 
acute event, 141 deceased within the first three years after registration. 27 
women did not survive the first year after onset of acute myocardial infarction 
and 58 died within the first three years after their event. 
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Table 5: Crude mortality in men and women for different times of follow-up 
Follow-up time Men Study period  
  ≤31dec99 >31dec99 all 
 
Number of 
persons 
1147 1064 2211 
1 year follow-up Number of deaths 34 28 62 
 Person years 1122.46 1038.6 2161.06 
 Mortality* 30.29 26.96 28.69 
     
3 years follow-up Number of deaths 81 60 141 
 Person years 3283.99 2927.77 6211.76 
 Mortality* 24.67 20.49 22.7 
     
total follow-up Number of deaths 248 83 331 
 Person years 8508.53 4033.08 12541.6 
 Mortality* 29.15 20.58 26.39 
    
  
Follow-up time Women Study period  
  ≤31dec99 >31dec99 all 
 
Number of 
persons 
373 327 700 
1 year follow-up Number of deaths 16 11 27 
 Person years 359.26 316.13 675.39 
 Mortality* 44.54 34.8 39.98 
     
3 years follow-up Number of deaths 37 21 58 
 Person years 1048.11 888.17 1936.27 
 Mortality* 35.3 23.64 29.95 
     
total follow-up Number of deaths 97 36 133 
 Person years 2736.27 1209.38 3945.65 
 Mortality* 35.45 29.77 33.71 
* rates per 1000 person years 
 
The Kaplan Meier survival curves for mortality in figures 9 and 10 show an 
almost identical survival for the two study periods in both sexes when adjusted 
for age. The p-values of the corresponding log-rank tests are 0.2693 for men 
and 0.9236 for women. 
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Figure 9: Kaplan Meier survival curve for mortality of men 
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Figure 10: Kaplan Meier survival curve for mortality of women 
 
Cox models were built to compare the mortalities of the two study periods 
through the total follow-up time. The hazard ratio (HR) in an unadjusted model 
for Study period 2 compared to Study period 1 is 0.86 (p-value= 0.270, 95% CI 
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0.65 to 1.13) for men and 0.98 (p-value= 0.924, 95% Confidence interval 0.64 
to 1.50) in women (table 6). With adjustment for age (model 2) only slight 
changes of the HR can be seen. In the fully adjusted model (model 3) the HR 
for men is 0.78 (p-value= 0.211, 95% CI 0.52 to 1.16) and the tendency of a 
reduced risk of mortality is more pronounced than in the first two models. This 
tendency cannot be found for women for whom the HR for mortality in the fully 
adjusted model is 1.37 (p-value= 0.254, 95% CI 0.80 to 2.36) which is 
consistent with no improved survival for women, who had their first AMI after 
the 31st December 1999 (table 6). 
 
Table 6: Gender specific mortality Hazard ratios and 95% C.I. for index event in 
Study Period 2 compared to Study Period 1 
 
 
 
 
 
 
 
 
 
* variables included age, angina pectoris, stroke, diabetes, education, working status, 
area of residence, ace-inhibitors, PCI, lysis, stent, bypass  
** variables included age, stroke, diabetes, lysis, stent, β-blockers, statins, ace-
inhibitors 
 
 
3.5 Re-infarction rate 
To evaluate the rates of re-infarction the same procedures were used as for 
the evaluation of mortality, but the follow-up times were censored in the case 
of death, at the 75th birthday, at the day of moving out of the study area or at 
the 31st December 2005. Crude re-infarction rates were calculated for one 
Mortality Model Hazard ratio 95% Confidence interval p-value 
   
 
Men 
1 0.86 0.65 1.13 0.270 
2 0.83 0.63 1.10 0.189 
 3* 0.78 0.52 1.16 0.211      
Women 
1 0.98 0.64 1.50 0.924 
2 0.94 0.62 1.45 0.793 
3** 1.37 0.80 2.36 0.254 
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year, three years and total time of follow-up and are presented in table 7.  In 
total 123 men suffered a re-infarction within the time of follow-up. Re-infarction 
rates are similar for men in both periods of time when calculated for the full 
time and three years of follow-up. The re-infarction rates within the first year of 
follow-up are 17.48 for the first cohort and 25.77 for the second. 35 women 
were affected by a re-infarction during follow-up. The rates differ between the 
two periods of time for all follow-up times. The re-infarction rates are generally 
lower for women with first AMI after the 31st of December 1999 (table 7). But 
these differences are hardly seen in the according age adjusted Kaplan Meier 
survival curves for re-infarction (figures 11 and 12), the p-values of the 
corresponding log rank tests are 0.9117 for men and 0.0531 for women. 
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Table 7: Crude re-infarction rates in men and women for different times of follow-up 
Follow-up time Men Study period  
  ≤31dec99 >31dec99 all 
 Number of cases 1147 1064 2211 
1 year follow-up Number of re-AMIs 19 26 45 
 Person years 1086.71 1009.01 2095.72 
 Re-infarction rate* 17.48 25.77 21.47 
     
3 years follow-up Number of re-AMIs 39 35 74 
 Person years 3068.08 2740.22 5808.3 
 Re-infarction rate* 12.71 12.77 12.74 
     
total follow-up Number of re-AMIs 80 43 123 
 Person years 7165.37 3675.24 10840.6 
 Re-infarction rate* 11.16 11.7 11.35 
    
  
Follow-up time Women Study period  
  ≤31dec99 >31dec99 all 
 Number of cases 373 327 700 
1 year follow-up Number of re-AMIs 8 1 9 
 Person years 348.4 303.64 652.04 
 Re-infarction rate* 22.96 3.29 13.8 
     
3 years follow-up Number of re-AMIs 17 5 22 
 Person years 938.89 796.97 1735.86 
 Re-infarction rate* 18.11 6.27 12.67 
     
total follow-up Number of re-AMIs 28 7 35 
 Person years 2074.04 1034.54 3108.58 
 Re-infarction rate* 13.5 6.77 11.26 
* rates per 1000 person years 
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Figure 11: Kaplan Meier survival curve for re-infarction rate of men 
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Figure 12: Kaplan Meier survival curve for re-infarction rate of women 
 
These results are confirmed for men by the Cox Proportional Hazards models 
with a HR of 1.02 (p-value= 0.912, 95% CI 0.68 to 1.53) in the unadjusted 
model (model 1) and 0.91 (p-value= 0.679, 95% CI 0.57 to 1.44) in the fully 
adjusted model (model 3) (table 8). For women on the other hand the risk of 
re-infarction is more than halved after the 31st of December 1999 with HRs of 
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0.44 (p-value= 0.059, 95% CI 0.19 to 1.03) and 0.4 (p-value= 0.040, 95% CI 
0.17 to 0.96) in the unadjusted and the fully adjusted model. 
 
Table 8: Gender specific re-infarction rate Hazard ratios and 95% C.I. for index event 
(first AMI) in Study Period 2 compared to Study Period 1 
Re-infarction rate Model Hazard ratio 95% Confidence interval p-value
      
Men 
1 1.02 0.68 1.53 0.912 
2 1.02 0.68 1.53 0.909 
3* 0.91 0.57 1.44 0.679 
      
Women 
1 0.44 0.19 1.03 0.059 
2 0.44 0.19 1.03 0.059 
3** 0.40 0.17 0.96 0.040 
 
* variables included age, education, angina pectoris, PCI, bypass, ex-smoking 
** variables included age, working status, hypertension 
 
 
 
3.6 The association of survival with treatment 
 
Age adjusted prevalence, mortality, re-infarction rate and the according cox 
models were calculated comparing two treatment groups, namely the patients 
without stent were compared with the patients who had received stents. The 
age adjusted prevalence differs significantly for the variables “men”, “living 
alone”, “working”, “angina pectoris”, “hypertension”, “hyperlipidemia”, “ex-
smoker” and all treatments (Table 9). 
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Table 9: Age adjusted prevalence of socio-demographic characteristics, pre-existing 
diseases and cardiovascular risk factors in treatment group with and without stent 
 
 Treatment  
Variable No stent Stent   
 Prevalence 95%-C.I. Prevalence 95%-C.I. *p-value 
Men 75.3 73.4 77.2 80.6 77.8 83.2 0.0025 
Urban 48.8 46.6 50.9 46.5 43.1 49.9 0.2669 
Education time≥ 12 years 11.4 10 13.1 13.3 11 16 0.2035 
Married 77.8 75.9 79.6 74.3 71.3 77.2 0.0478 
Living alone 13.1 11.7 14.7 15.7 13.4 18.4 0.0753 
Working 35.4 32.6 38.4 41.1 36.6 45.9 0.0399 
  
Angina pectoris 12.8 11.4 14.3 9.5 7.7 11.7 0.0144 
Hypertension 62 59.8 64.1 71.2 67.9 74.2 <.0001 
Hyperlipidemia 69.4 67.3 71.4 79.2 76.3 81.8 <.0001 
Stroke 4.2 3.4 5.3 4.3 3.1 6 0.9223 
Diabetes 25.1 23.3 27 24.1 21.3 27.2 0.5792 
   
BMI ≥ 30 kg/m2 18.8 17.1 20.5 21 18.3 23.9 0.1768 
Never smoker 30.3 28.2 32.5 27.5 24.3 30.8 0.154 
Ex smoker 25.7 23.8 27.7 29.5 26.4 32.8 0.0452 
Current smoker 40.6 38.3 43 39.1 35.5 42.9 0.5169 
        
Lysis 41.5 39.4 43.6 26.7 23.8 29.8 <.0001 
PCI w/o stent 20.4 18.7 22.2         
Bypass 17.1 15.6 18.8 1.7 1 2.8 <.0001 
Antiplatelets 89.9 88.5 91.2 98.6 97.5 99.2 <.0001 
β-Blockers 87.7 86.2 89.1 96.3 94.7 97.4 <.0001 
Statins 49.7 47.5 51.8 84.8 82.1 87.1 <.0001 
ACE-inhibitors 50.3 48.1 52.5 82.7 80 85.1 <.0001 
*p-value derived through logistic regression by comparing the two treatment groups 
regarding the age adjusted prevalences of each treatment 
 
 
 
 
The crude mortality is lower for men and women who were treated with PCI 
and stent compared to persons without this kind of treatment. During total 
follow-up 331 men and 133 women died of whom only 40 respectively 8 had 
received a stent. The difference of crude mortality was higher in women than 
in men. 
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Table 10: Crude mortality in men and women for different times of follow-up in the 
two treatment groups 
 
Follow-up time Men Stent  
  no yes all 
 Number of cases 1537 672 2209 
1 year follow-up Number of deaths 54 8 62 
 Person years 1494.26 664.8 2159.06 
 Mortality* 36.14 12.03 28.72 
     
3 years follow-up Number of deaths 112 29 141 
 Person years 4338.15 1867.61 6205.76 
 Mortality* 35.3 20.49 22.72 
     
total follow-up Number of deaths 291 40 331 
 Person years 9928.91 2599.57 12528.48
 Mortality* 29.31 15.39 26.42 
    
  
Follow-up time Women Stent  
  no yes all 
 Number of cases 537 163 700 
1 year follow-up Number of deaths 25 2 27 
 Person years 517.52 157.87 675.39 
 Mortality* 48.31 12.67 39.98 
     
3 years follow-up Number of deaths 55 3 58 
 Person years 1486.63 449.64 1936.27 
 Mortality* 37 6.67 29.95 
     
total follow-up Number of deaths 125 8 133 
 Person years 3317.58 628.07 3945.65 
 Mortality* 37.68 12.74 33.71 
*per 1000 person years  
 
Table 11 summarises the hazard ratios from different cox models regarding 
the mortality in the group with and the group without stent. The hazard ratio in 
the fully adjusted model (model 3) for men is 0.66 with a p-value of 0.042 
(95% C.I. 0.44 to 0.99) which represents a reduction in mortality of 34% for 
men who were treated with stent. This reduction is even higher for women, 
whose hazard ratio in the fully adjusted model (model 3) is 0.46 (p-
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value=0.042; 95% C.I. 0.22 to 0.97) which corresponds to a reduction of 
mortality over 50% after the introduction of stents. 
 
Table 11: Gender specific mortality Hazard ratios and 95% C.I. comparing the group 
with stent to the group without stent 
 
Mortality Model Hazard ratio 95% Confidence interval p-value 
men 
1 0.60 0.43 0.84 0.003 
2 0.65 0.47 0.92 0.015 
3* 0.66 0.44 0.99 0.042 
      
women 
1 0.37 0.18 0.76 0.007 
2 0.36 0.18 0.75 0.006 
3** 0.46 0.22 0.97 0.042 
*variables included age, angina pectoris, stroke, diabetes, education, working status, 
area of residence, ace-inhibitors 
** variables included age, stroke, diabetes, β-blockers, statins, ace-inhibitors 
 
The crude re-infarction rate in men is higher for those who received stents. 
The rate is especially high within the first year of follow-up. The treatment has 
almost no effect on the re-infarction rate of women, where the total number of 
re-infarctions is 35 and therefore very low. 
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Table 12: Crude re-infarction rate in men and women for different times of follow-up 
in the two treatment groups 
 
Follow-up time Men Stent  
  no yes all 
 Number of cases 1537 672 2209 
1 year follow-up Number of re-AMIs 24 21 45 
 Person years 1450.42 643.3 2093.72 
 Re-infarction rate* 16.55 32.64 21.49 
     
3 years follow-up Number of re-AMIs 46 28 74 
 Person years 4064.78 1737.53 5802.3 
 Re-infarction rate* 11.32 16.11 12.75 
     
total follow-up Number of re-AMIs 92 31 123 
 Person years 8463.25 2364.24 10827.48
 Re-infarction rate* 10.87 13.11 11.36 
    
  
Follow-up time Women Stent  
  no yes all 
 Number of cases 537 163 700 
1 year follow-up Number of re-AMIs 8 1 9 
 Person years 499.25 152.79 652.04 
 Re-infarction rate* 16.02 6.55 13.8 
     
3 years follow-up Number of re-AMIs 20 2 22 
 Person years 1334.04 401.83 1735.86 
 Re-infarction rate* 14.99 4.98 12.67 
     
total follow-up Number of re-AMIs 29 6 35 
 Person years 2577.08 531.5 3108.58 
 Re-infarction rate* 11.25 11.29 11.26 
*per 1000 person years 
 
The results from the crude re-infarction rates are confirmed by the according 
hazard ratios which are not significant in both sexes as can be seen in table 
13. 
 
 
 
 41
Table 13: Gender specific re-infarction rate Hazard ratios and 95% C.I. comparing 
the two treatment groups 
 
Re-infarction rate Model Hazard ratio 95% Confidence interval p-value
Men 
1 1.18 0.78 1.81 0.437 
2 1.21 0.79 1.85 0.378 
3* 1.15 0.73 1.84 0.545 
      
Women 
1 0.94 0.38 2.29 0.887 
2 0.94 0.38 2.29 0.888 
3** 0.91 0.36 2.25 0.832 
*variables included age, education, ex-smoking, bypass 
**variables included age, working status, hypertension 
 
4. Discussion 
4.1 Aims of the study 
The two major endpoints of this study were long-term mortality and re-
infarction rate in 28-day survivors after first myocardial infarction in the light of 
changing therapeutic guidelines and diagnostic criteria. Survival improved 
since the year 2000 when the new therapeutic guidelines were implemented, 
although the reduction in mortality was not significant. On the other hand the 
re-infarction rate remained unchanged for men when comparing Study Period 
1 and 2 while for women it decreased after the year 2000, but the total number 
of 35 cases of re-infarction during the complete follow-up time is small and this 
result must therefore be treated with caution. 
 
 4.2 The role of changes in diagnostic criteria, risk factors and treatment 
 
4.2.1 The role of changing diagnostic criteria 
 
In the beginning of the study it was planned to include patients from the two 
categories “definite” and “possible” AMI into the analysis.  But it was important 
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that the two groups of patients from Study Period 1 and 2 were as similar as 
possible concerning the severity of their AMI.  The WHO-MONICA criteria for 
acute myocardial infarction are based on symptoms, changes in 
electrocardiograms and the concentrations of the cardiac enzymes CK, CK-
MB, LDH and GOT. These criteria are still used in the algorithm to create the 
four diagnostic categories of AMI.  Since the year 2000 the inclusion of raised 
Troponin concentration in the diagnostic criteria has been recommended as a 
more sensitive marker of cardiac muscle damage by the European Society of 
Cardiology and the American College of Cardiology. This led to an increase of 
clinically diagnosed cases of acute myocardial infarction, which were earlier 
treated as unstable angina pectoris (Koukkunen, Penttila et al. 2001; Pell, 
Simpson et al. 2003; Salomaa, Koukkunen et al. 2005; White 2008). Salomaa 
et al. found 83% more definite AMIs using the new definition compared to the 
WHO MONICA definition. They state that about one third of these additional 
cases of AMI were classified as possible AMIs by the WHO MONICA 
definition. Roger et al. reported not only an increase in diagnosed AMIs, but 
also found a change in the case mix of patients with AMI, who were older, 
more likely to be female with lower Killip class and more non-ST-elevation 
ECG (Roger, Killian et al. 2006). The CER in Augsburg using the WHO 
MONICA definition of AMI has registered more cases of possible AMI since 
the year 2000, as is shown in figure 2 and 3, which is probably due to the 
application of the new guidelines from the ACC and ESC by the CER (Kuch, 
Heier et al. 2008). This result led to the conclusion that the category of 
possible AMI from before the year 2000 differs from the same category since 
the year 2000 concerning the nature of AMIs and these cases were therefore 
excluded from the analysis. It is also possible that more cases of definite AMI 
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are identified through the application of the new diagnostic criteria by 
clinicians. These cases might be less severe, what would explain the increase 
of 28-day survivors with definite AMI. 
 
4.2.2 Age-adjusted prevalence of cardio-vascular risk factors 
 
The patients of Study Period 2 reported significantly more diabetes, high blood 
pressure, stroke, obesity and hyperlipidaemia. These results are in 
accordance with the international literature where the raising trend of these 
conditions due to changing dietary patterns and an increasingly sedentary 
lifestyle in the general population has been stated repeatedly (King, Aubert et 
al. 1998; Pradhan, Skerrett et al. 2002; Wilborn, Beckham et al. 2005; 
Pradhan 2007; Centers for Disease Control and Prevention [rev. 26 Mar 2007; 
cited 3 Dec 2007].).  Long-term mortality in men and women with diabetes is 
significantly higher after a first AMI (Koek, Soedamah-Muthu et al. 2007). 
Evans et al. on the other hand found declining 10 year trends of blood 
pressure and serum cholesterol in the majority of the 38 populations of 21 
countries of the WHO MONICA project (Kuulasmaa, Tunstall-Pedoe et al. 
2000; Evans, Tolonen et al. 2001), but they confirmed the upwards trends in 
body mass index in both sexes.  The proportion of smokers was lower in 
patients of Study Period 2 and the proportion of ex-smokers was accordingly 
significantly higher, a trend, which has also been reported by Evans et al. and 
Kuulasmaa et al. It is possible that the patients of the present study reflect the 
trends in the general population, but other explanations for the increase in 
prevalence of pre-existing illnesses are possible. Since the introduction of the 
new therapeutic guidelines more patients survived the first 28 days after their 
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first myocardial infarction which is in accordance to the current literature 
(Buch, Rasmussen et al. 2007; Fox, Steg et al. 2007) and it seems plausible 
that these patients are less healthy and owe their survival to the new treatment 
strategies. Another explanation is the risen awareness in the general 
population and doctors concerning cardio-vascular risk factors (Böhm M 
2008).  More patients received preclinical treatment of hypertension or 
diabetes and therefore report these conditions in the interview of the CER. The 
higher prevalence of pre-existing illnesses in patients of Study Period 2 is a 
possible reason for the non-significance of the hazard ratios for mortality, if the 
increase of illnesses is real and not generated through a higher rate of 
diagnosis. 
 
4.2.3. The role of new treatment strategies  
 
The prescription of antiplatelet medication, β-blockers, ACE-inhibitors and 
statins has risen continuously since 1995 to a level of over 95% for antiplatelet 
medication and β-blockers and of over 85% for ACE-inhibitors and statins. 
This trend has been seen by Goldberg et al. in 2007, who studied the use of 
single and combination medical drug therapy from patients included in the 
Global Registry of Acute Coronary Events (GRACE) between 2000 and 2005 
(Goldberg, Spencer et al. 2007) and by Setoguchi et al. (Setoguchi, Glynn et 
al. 2008), whereas Hasdai et al. stated in 2002 that acute coronary syndrome 
(ACS) patients are often treated according to routine and not to the current 
practice guidelines (Hasdai, Behar et al. 2002), because they found lower 
levels of the respective discharge medications (Aspirin 88.5%, ACE-inhibitors 
60.7%, β-blockers 76.1% and statins 54%) for patients with ST-elevation 
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myocardial infarction from 25 European countries. The level of PCI treatments 
in their population was 40.4% in the end of the year 2000 and the first half of 
2001, whereas over 50% of the CER patients had received a stent in 2001 
increasing to 65% in the year 2003. The implementation of the new treatment 
strategies seems to have worked well in the participating hospitals in 
Augsburg. The prompt enactment of the practice guidelines is probably partly 
due to the fact that the Augsburg Central Clinic, where around 85% of the 
patients were treated, is one of the teaching hospitals of the University of 
Munich with angiography, PCI and heart surgery facilities. 
The discharge medication plays an important role in secondary prevention and 
is known to reduce mortality after a first AMI (Smith, Jackson et al. 2004; 
Setoguchi, Glynn et al. 2008). Primary PCI reduces the risk of non-fatal re-
infarction, short-term and long-term mortality in randomized trials and large 
prospective studies (Keeley, Boura et al. 2003; Muhlestein, Anderson et al. 
2005; Stenestrand, Lindback et al. 2006). These positive effects are not clearly 
confirmed by the present study when comparing the patients of the two study 
periods, because the trend for a reduced mortality is not significant for men 
and women and the hazard ratio for re-infarction stayed the same before and 
after the introduction of the new therapeutic guidelines. The mortality hazard 
ratio in patients with PCI and stent compared with other patients is significant 
for men and women after full adjustment for possible confounders. This 
difference in outcomes is difficult to explain, because before the year 2000 
only few patients received PCI and stents so that the comparison of the two 
time periods should reflect this fact, but other factors seem to influence the 
mortality which was not adjusted for. Tables 3 and 9 show the age-adjusted 
prevalences of risk factors for the two study periods and for patients with and 
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without stent. The age-adjusted prevalence of diabetes is significantly higher 
in Study Period 2, but there is no significant difference in age-adjusted 
prevalence of diabetes between patients with or without stent. On the other 
hand significantly more patients, who received a stent, are still working, 
whereas the prevalence of working patients is similar in Study Period 1 and 2. 
History of diabetes and the working status were included in the Cox models 
and should not influence the results, but it becomes clear that patients with 
stent are probably healthier (healthy worker effect) and have therefore a better 
chance of survival. Buiatti et al state that physicians tend to select less severe 
cases of AMI for reperfusion treatment (Buiatti, Barchielli et al. 2003; Balzi, 
Barchielli et al. 2008) which would explain a better outcome for patients with 
stent in the presented study population. Nieuwlaat et al. found that patients 
with a previous PCI and long pre-hospital delay, who arrived in a hospital with 
PCI-facilities and did not participate in a clinical trial, were more likely to 
receive PCI-treatment. Although the present study confirms that physicians in 
the Augsburg hospitals adhere well to current practice guidelines, hospital 
culture may still influence the decision which treatment is used and therefore 
leads to an undeterminable selection of patients (Hasdai, Behar et al. 2002; 
Nieuwlaat, Lenzen et al. 2006). 
 
4.3 Strengths and limitations 
 
The present study is a population based epidemiologic cohort study 
addressing the changes in survival after myocardial infarction due to changes 
of therapeutic measures since the year 2000. It represents the conditions of a 
real life setting which differ from the conditions of a randomized controlled trial 
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in that selection bias is reduced. The decision whether a patient is treated with 
PCI and stent should be based on current guidelines, but individual judgement 
by the treating physician and hospital culture influence (Buiatti, Barchielli et al. 
2003; Nieuwlaat, Lenzen et al. 2006) this decision and a certain degree of 
selection bias cannot completely be avoided. Patients have been recruited by 
the same means and nurses almost since the beginning of the CER. The 
internal validity of data has to be considered as very strong, because of the 
long existing routine of interviewing and record handling. Interviews are 
conducted shortly after the event (2 to 3 days after) to minimize recall bias 
concerning the event. The information on pre-existing illnesses which is also 
retrieved through the interview is confirmed through the medical records and 
information bias can be excluded in this respect. 
One of the limitations of the study is that time to treatment has not been 
considered as a predicting risk factor for survival after myocardial infarction (de 
Labriolle, Pacouret et al. 2008). Information on drug compliance and eventual 
alteration of the discharge medication through the treating physician after 
discharge from the hospital was not available. The Cox models were 
calculated using the discharge medication, which will differ from the actual 
medication to a degree, which is unknown. 
Finally it has to be stated that the results from this study cannot be generalized 
to other regions with a different hospital infrastructure, because the facilities at 
the Central Clinic Augsburg are better equipped to treat myocardial infarctions 
than many smaller hospitals in more rural areas. The generalizability is also 
reduced through the age limit which excludes patients to participate in the 
study after their 75th birthday. The effect of the new treatment strategies might 
differ for older patients in both directions. It is thinkable that they profit even 
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more from the new treatments and their mortality decreases, but because of 
more severe pre-existing illnesses the effect of new treatments could also be 
reduced. A separate study and analysis of this patient group is warranted 
because especially women are affected by myocardial infarction more in their 
later years. 
 
4.4 Conclusions 
  
In the present study a decreasing trend of mortality after first AMI was 
observed in 25 to 74 year old men and women between the years 1995 and 
2005 albeit the reduction was not significant. The re-infarction rate after the 
index event remained stable in the same time period. Patients who received a 
PCI with stent showed significantly lower mortality during follow-up, but their 
re-infarction rate stayed unchanged when compared to patients without PCI 
and stent. Residual confounding could not be excluded completely and might 
be responsible for the differing results comparing time periods or treatment 
groups.  
The new therapeutic guidelines have been successful implemented in the 
study hospitals with high rates of PCI with stent and prescription of the 
recommended discharge medication. 
These findings confirm the current publications concerning the comparison of 
therapeutic measures in a real life setting and the realisation of the new 
therapeutic guidelines.  
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5. Summary 
 
The introduction of new invasive therapies for acute myocardial infarction and 
new medication schemes for secondary prevention is thought to increase life 
expectancy in 28-day survivors of a first myocardial infarction. The present 
thesis examined mortality and re-infarction rate of those patients in the light of 
changed therapeutic guidelines.  
Cases of 25 to 74 year old 28-day survivors of a first definite AMI based on 
MONICA criteria were identified in the Coronary Event Registry in Augsburg, 
Southern Germany, who had their index event between the 1st of January 
1995 and the 31st of December 2003. Information on patients was gathered 
through personal interviews shortly after the event and the processing of 
medical records for relevant data. Mortality follow-up was done by registration 
of deaths which occurred until 31st of December 2005. Re-infarctions were 
registered in the CER if they were suffered before the 75th birthday of a patient 
and/or 31st of December 2005. Patients were divided into two groups 
depending on the year of the index event. Patients with AMI before the 31st of 
December 1999 belonged to Study period 1, patients who had their first AMI 
between the years 2000 and 2003 belonged to Study period 2. Mortality and 
re-infarction rates were calculated for 1 year, 3 years and total follow-up for 
both study periods and separately for men and women. Cox models were built 
to compare the rates of Study period 1 and 2 including possible confounding 
factors. Additionally the same calculations were performed comparing patients 
who received PCI with stent with all other patients. 
Of the total number of registered cases 2911 persons with definite MI survived 
the first 28 days after the event. Crude mortality was higher in Study period 1 
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than in Study period 2 and higher for women than for men. Re-infarction rates 
remained stable for men during both study periods, but women from Study 
period 1 had a much higher re-infarction rate than women in Study period 2.  
The hazard ratios showed no significant differences for mortality and re-
infarction in men. Hazard ratios of re-infarction in women were significantly 
reduced, but have to be treated with caution as the number of re-infarctions 
during Study period 2 was very small. Mortality hazard ratios in women were 
also not significant. When comparing patients with PCI and stent with all other 
patients the hazard ratios for mortality in men and women were significantly 
reduced. In contrast hazard ratios for re-infarctions were not significantly 
reduced.  
The results confirm that stents reduce the mortality of patients who survived 
their first AMI for more than 28 days in a real life setting, but when comparing 
the time periods before and after the introduction of stent as a routine therapy 
with the implementation of new therapeutic guidelines the effect is not seen. 
Several reasons are probably responsible for this finding. The population of 
patients has changed with respect to their risk factors and new diagnostic 
criteria may have also contributed. Further studies are needed to illuminate 
these questions. 
 
6. Zusammenfassung 
Die Einführung neuer invasiver Therapien zur Behandlung des akuten 
Myokardinfarkts und neuer medikamentöser Therapieempfehlungen zur 
Verbesserung der sekundären Prävention sollten zu einer Verlängerung des 
Lebens von Patienten führen, die ihren ersten akuten Herzinfarkt mehr als 28 
Tage überlebt haben. In der vorliegenden Arbeit wurde der Zusammenhang 
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zwischen Mortalität und Reinfarktrate dieser Patienten und den neueren 
Therapieverfahren untersucht. 
Patienten, die zwischen 25 und 74 Jahre alt waren und die ersten 28 Tage 
nach ihrem ersten Herzinfarkt überlebt hatten, wurden im MONICA/KORA-
Herzinfarktregister, Augsburg, identifiziert. Der Erstinfarkt musste zwischen 
dem 1. Januar 1995 und dem 31. Dezember 2003 statt gefunden haben. 
Durch persönliche Interviews kurz nach dem Ereignis und die Bearbeitung der 
Krankenakten wurden relevante Daten zu den Fällen erhoben. Todesfälle und 
Reinfarkte wurden kontinuierlich registriert. Als Ende der Folgebeobachtung 
wurde für die Mortalität  der 31. Dezember 2005 festgelegt. Für die 
Berechnung der Reinfarktrate galt der 75. Geburtstag oder der 31. Dezember 
2005 als Endpunkt. Die Patienten wurden in zwei Gruppen eingeteilt. Die erste 
Gruppe hatte ihren Erstinfarkt zwischen dem 1. Januar 1995 und dem 31. 
Dezember 1999 (Studiengruppe 1), in der zweiten Gruppe waren die 
Patienten, die zwischen dem 1. Januar 2000 und dem 31. Dezember 2003 
ihren ersten akuten Herzinfarkt hatten (Studiengruppe 2). Mortalität und 
Reinfarktraten wurden für 1 Jahr, 3 Jahre und den gesamten 
Beobachtungszeitraum getrennt nach Studiengruppe und Geschlecht 
berechnet. Cox Modelle wurden erstellt um die Raten der Studiengruppen 
unter Einbeziehung möglicher Confounder zu vergleichen. Die gleichen 
Berechnungen wurden durchgeführt, um Patienten mit Stent- Behandlung mit 
Patienten ohne Stent-Behandlung zu vergleichen.  
Von der Gesamtzahl der registrierten Patienten überlebten 2911 Personen mit 
definitivem Herzinfarkt die ersten 28 Tage nach dem Ereignis. Die Mortalität 
der Patienten in Studiengruppe 1 war höher als die Mortalität in Studiengruppe 
2 und höher für Frauen als für Männer. Die Reinfarktraten waren für Männer in 
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beiden Gruppen statistisch nicht unterschiedlich, während die Frauen in der 
ersten Gruppe eine wesentlich höhere Reinfarktrate hatten als die Frauen der 
zweiten Gruppe. Die Hazard Ratios unterschieden sich bei den Männern 
weder für die Mortalität noch für die Reinfarktraten. Bei den Frauen waren die 
Hazard Ratios für Reinfarkte zwar signifkant, müssen aber mit Vorsicht 
behandelt werden, da die Anzahl der Reinfarkte  im Zeitraum 2000-2003 sehr 
klein ist. Die Hazard Ratios für Mortalität waren bei den Frauen ebenfalls nicht 
signifikant. Bei dem Vergleich von Patienten mit und ohne Stent zeigte sich 
eine signifikante Reduktion der Mortalität bei Männern und Frauen, während 
sich die Reinfarktraten nicht signifikant veränderten.  
Die vorliegenden Ergebnisse bestätigen, dass die Behandlung mit Stents die 
Mortalität bei Patienten, die den ersten Infarkt mindestens 28 Tage überlebt 
haben, unter klinischen Bedingungen reduziert. Der Vergleich der beiden 
Zeiträume vor der offiziellen Empfehlung zur Therapie mit Stent und nach der 
Einführung der neuen Therapierichtlinien zeigt keine Verbesserung. Die 
Gründe hierfür sind wahrscheinlich sehr komplex und können mit der 
Veränderung der diagnostischen Kriterien sowie der Veränderung der 
Patientenpopulation zu tun haben. Es werden weitere Studien benötigt, um 
diese Fragen beantworten zu können. 
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